AMI Asset Management Corp Has $1.79 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

AMI Asset Management Corp trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,460 shares of the biopharmaceutical company’s stock after selling 11,484 shares during the quarter. AMI Asset Management Corp’s holdings in Halozyme Therapeutics were worth $1,791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Boston Trust Walden Corp boosted its holdings in Halozyme Therapeutics by 54.0% in the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after purchasing an additional 239,321 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after buying an additional 209,530 shares during the last quarter. Finally, South Street Advisors LLC bought a new position in Halozyme Therapeutics during the third quarter valued at about $9,812,000. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Finally, JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Trading Down 1.0 %

Halozyme Therapeutics stock opened at $54.80 on Tuesday. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The stock has a market cap of $6.97 billion, a price-to-earnings ratio of 18.15, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. The business has a 50 day moving average price of $49.50 and a two-hundred day moving average price of $54.14. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.